We are live on ! Find out more
MCM

M28 Capital Management Portfolio holdings

AUM $53.8M
1-Year Est. Return 28.63%
This Fund
S&P 500
This Quarter Est. Return
+38.64%
1 Year Est. Return
+28.63%
3 Year Est. Return
+218.52%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$87.2M
AUM Growth
+$11.5M
Cap. Flow
-$4.33M
Cap. Flow %
-4.96%
Top 10 Hldgs %
99.97%
Holding
12
New
–
Increased
2
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
CRIS icon
Curis
CRIS
+$1.57M
2
TGTX icon
TG Therapeutics
TGTX
+$1.03M

Top Sells

Rank Stock Value
1
STOK icon
Stoke Therapeutics
STOK
+$3.68M
2
RCKT icon
Rocket Pharmaceuticals
RCKT
+$1.95M
3
BBIO icon
BridgeBio Pharma
BBIO
+$1.28M
4
WVE icon
Wave Life Sciences
WVE
+$25.1K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WVE icon
1
Wave Life Sciences
WVE
$1.12B
$40.5M 46.45%
7,044,500
-5,500
-0.1% -$25.1K
IVVD icon
2
Invivyd
IVVD
$180M
$15.7M 18.03%
9,248,250
– –
RCKT icon
3
Rocket Pharmaceuticals
RCKT
$348M
$10.7M 12.3%
523,280
-107,100
-17% -$1.95M
SWTX
4
DELISTED
SpringWorks Therapeutics
SWTX
$4.57M 5.24%
197,700
– –
SLN
5
Silence Therapeutics
SLN
$521M
$3.57M 4.1%
363,800
– –
BBIO icon
6
BridgeBio Pharma
BBIO
$16.5B
$3.2M 3.67%
121,200
-45,000
-27% -$1.28M
CRIS icon
7
Curis
CRIS
$9.53M
$2.78M 3.19%
21,098
+6,098
+41% +$1.57M
PRQR icon
8
ProQR Therapeutics
PRQR
$243M
$2.48M 2.85%
1,910,600
– –
ARWR icon
9
Arrowhead Research
ARWR
$12.1B
$1.81M 2.08%
67,400
– –
TGTX icon
10
TG Therapeutics
TGTX
$8.58B
$1.81M 2.08%
216,600
+74,100
+52% +$1.03M
NEXI
11
DELISTED
NexImmune, Inc. Common Stock
NEXI
$28K 0.03%
5,338
– –
STOK icon
12
Stoke Therapeutics
STOK
$1.82B
– –
-346,190
Closed -$3.68M

Similar funds

NCM
Notable Capital Management Menlo Park, California $53.4M AUM 10.98% 1-Year Est. Return
WEO
William E. Oberndorf $53.3M AUM 10.89% 1-Year Est. Return
MML
Mercato Management Legacy Cottonwood Heights, Utah $54.3M AUM
CAM
Copperwood Asset Management Houston, Texas $54.4M AUM
ETCM
Evolutionary Tree Capital Management Alexandria, Virginia $53.2M AUM 13.56% 1-Year Est. Return
AA
Ascent Advisors Mankato, Minnesota $54.4M AUM
TP
Toronado Partners San Francisco, California $53M AUM 13.38% 1-Year Est. Return
GMEI
Global Media & Entertainment Investments Nassau, Bahamas $53M AUM 0% 1-Year Est. Return

M28 Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, M28 Capital Management held 12 positions worth $87.2M, up 15% from $75.7M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

M28 Capital Management withdrew a net $4.33M in Q3 2023, closing 1 position and reducing 3 holdings. Its most notable exit was Stoke Therapeutics, an estimated $3.68M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, M28 Capital Management added an estimated $1.57M to Curis.

  • M28 Capital Management added most to Curis in Q3 2023, an estimated $1.57M increase.
  • M28 Capital Management's biggest Q3 2023 reduction was Rocket Pharmaceuticals, cutting an estimated $1.95M.
  • M28 Capital Management fully exited Stoke Therapeutics in Q3 2023, selling an estimated $3.68M.
  • M28 Capital Management's ten largest holdings make up 100% of its $87.2M portfolio in Q3 2023.
  • M28 Capital Management opened 0 new positions and closed 1 in Q3 2023.
  • M28 Capital Management's portfolio value rose 15% quarter-over-quarter to $87.2M.

Based on M28 Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.